Abbonarsi

Identification of urinary biomarkers of synthetic cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID and BZO-CHMOXIZID from authentic urine samples in Singapore - 15/08/22

Doi : 10.1016/j.toxac.2022.06.155 
Hian Twan Chang 1, , Ching Yee Fong 1, Keane Zhi Hao Lee 2, Ziteng Wang 2, Eric Chun Yong Chan 2, Hooi Yan Moy 1
1 Analytical toxicology laboratory, Health sciences authority, Singapore, Singapore 
2 Department of pharmacy, National university of Singapore, Singapore, Singapore 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Aim

Following the implementation of a class-wide regulation on synthetic cannabinoids by China in July 2021, there was a notable decrease in the indole and indazole synthetic cannabinoids (SCs) worldwide. The same trend was observed in Singapore until recently, the new ‘OXIZID’ generation of SCs surfaced in seized materials, which included BZO-HEXOXIZID (MDA-19), BZO-POXIZID, 5F-BZO-POXIZID and BZO-CHMOXIZID. To detect the OXIZID abuse, it is crucial to identify the key urinary biomarkers of these OXIZIDs.

Method

The metabolites of the OXIZIDs were previously characterised in human liver microsomes (HLM) using an ultra-high-performance liquid chromatography coupled with Thermo Scientific Q-Exactive hybrid quadrupole-orbitrap mass spectrometer. Targeted masses of the metabolites were added to the detection list for screening on authentic urine samples collected from suspected OXIZIDs abusers. Metabolite peaks detected were then compared against the in vitro metabolite identification for their retention times and MS/MS spectra.

Results

Four authentic urine samples were found to contain parents and metabolites from one or more OXIZIDs. Metabolites of BZO-HEXOXIZID, BZO-POXIZID and 5F-BZO-POXIZID, generally the N-alkyl and phenyl mono-hydroxylated forms were consistently detected in the samples, alongside with the parent OXIZIDs, albeit at lower intensities compared to the mono-hydroxylated metabolites. N-alkyl di-hydroxylated metabolite was inconsistently present among the samples although some of which the identities were uncertain due to interference at the MS/MS spectrum. Parent and metabolites of BZO-CHMOXIZID were not detected from all the urine samples.

The range of metabolites detected in the authentic urine samples is in agreement with the in vitro metabolism study via HLM. The results of the metabolites of BZO-HEXOXIZID and BZO-POXIZID, in particular of those resulting from oxidative reactions at the N-alkyl chain, concur with that for similar straight-chain SCs such as JWH-018 and the more recent ADB-BUTINACA. Both BZO-POXIZID and its fluorinated analogue, 5F-BZO-POXIZID were observed to have overlapping metabolite profiles and proper selection of discerning biomarkers is thus required for each OXIZID.

Conclusion

With the emergence of OXIZIDs in Singapore and the rest of the world, our study serves as a reference to establish the urinary biomarkers for routine screening efforts and mitigate their abuse. Integrating with the authentic urine analyses, the parent drugs and both N-alkyl and phenyl mono-hydroxylated metabolites of BZO-HEXOXIZID, BZO-POXIZID and 5F-BZO-POXIZID were determined as suitable urinary biomarkers.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 34 - N° 3S

P. S100-S101 - Settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Automating DUID methods using robotics for rapid high throughput sample preparation – Analysis of Delta-9-Tetrahydrocannabinol and its major metabolite Delta-9-tetrahydrocannabinol acid in whole blood
  • Charlotte Cattell, Aaron Mcmillan, Mark Evans, Susan Grosse, Mark Parkin
| Articolo seguente Articolo seguente
  • Literature review on pregabalin and the risk of addiction
  • Akli Chebli

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.